All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Miltenyi Biomedicine, Nurix Therapeutics, Roche, Sobi, and Thermo Fisher Scientific and supported through educational grants from Bristol Myers Squibb, Lilly, and Pfizer. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
NICE recommends epcoritamab for R/R FL
On February 23, 2026, the National Institute for Health and Care Excellence (NICE) announced the recommendation of epcoritamab, an immunoglobulin G1 (IgG1) bispecific antibody, for the treatment of adult patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 lines of systemic therapy, if epcoritamab is stopped after 3 years of treatment or earlier if the lymphoma progresses.1
This recommendation is based on the results of the phase II EPCORE NHL-1 study (NCT03625037),1 which have previously been reported by the Lymphoma Hub. Of 128 patients with R/R FL enrolled in the study, the overall response rate (ORR) was 82.0%, with a complete response (CR) rate of 62.5%.2 The most common Grade ≥3 treatment-emergent adverse event (TEAE) was neutropenia (25%).2 Grade 1–2 cytokine release syndrome (CRS) was reported in 65% of patients, and Grade 3 CRS was reported in 2% of patients.2 Immune effector cell-associated neurotoxicity syndrome was reported in 6% of patients.2
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
.webp&w=3840&q=75)